Promotion of human mesenchymal stem cell osteogenesis by PI3-kinase/Akt signaling, and the influence of caveolin-1/cholesterol homeostasis by Baker, N et al.
RESEARCH Open Access
Promotion of human mesenchymal stem
cell osteogenesis by PI3-kinase/Akt
signaling, and the influence of
caveolin-1/cholesterol homeostasis
Natasha Baker1,2, Jihee Sohn1 and Rocky S. Tuan1*
Abstract
Introduction: Stem cells are considered an important resource for tissue repair and regeneration. Their utilization in
regenerative medicine will be aided by mechanistic insight into their responsiveness to external stimuli. It is likely
that, similar to all other cells, an initial determinant of stem cell responsiveness to external stimuli is the
organization of signaling molecules in cell membrane rafts. The clustering of signaling molecules in these
cholesterol-rich membrane microdomains can affect the activity, specificity, cross-talk and amplification of cell
signaling. Membrane rafts fall into two broad categories, non-caveolar and caveolar, based on the absence or
presence, respectively, of caveolin scaffolding proteins. We have recently demonstrated that caveolin-1 (Cav-1)
expression increases during, and knockdown of Cav-1 expression enhances, osteogenic differentiation of human
bone marrow derived mesenchymal stem cells (MSCs). The increase in Cav-1 expression observed during
osteogenesis is likely a negative feedback mechanism. We hypothesize that focal adhesion signaling pathways such
as PI3K/Akt signaling may be negatively regulated by Cav-1 during human MSC osteogenesis.
Methods: Human bone marrow MSCs were isolated from femoral heads obtained after total hip arthroplasty. MSCs
were incubated in standard growth medium alone or induced to osteogenically differentiate by the addition of
supplements (β-glycerophosphate, ascorbic acid, dexamethasone, and 1,25-dihydroxyvitamin D3). The activation of
and requirement for PI3K/Akt signaling in MSC osteogenesis were assessed by immunoblotting for phosphorylated
Akt, and treatment with the PI3K inhibitor LY294002 and Akt siRNA, respectively. The influences of Cav-1
and cholesterol membrane rafts on PI3K/Akt signaling were investigated by treatment with Cav-1 siRNA,
methyl-β-cyclodextrin, or cholesterol oxidase, followed by cellular sub-fractionation and/or immunoblotting
for phosphorylated Akt.
Results: LY294002 and Akt siRNA inhibited MSC osteogenesis. Methyl-β-cyclodextrin, which disrupts all membrane
rafts, inhibited osteogenesis. Conversely, Cav-1 siRNA and cholesterol oxidase, which displaces Cav-1 from caveolae,
enhanced Akt signaling induced by osteogenic supplements. In control cells, phosphorylated Akt began to accumulate
in caveolae after 10 days of osteogenic differentiation.
Conclusions: PI3K/Akt signaling is a key pathway required for human MSC osteogenesis, and it is likely that localization of
active Akt in non-caveolar and caveolar membrane rafts positively and negatively contributes to osteogenesis, respectively.
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Introduction
New bone formation may be desirable in a variety of
clinical settings, such as in osteoporosis, skeletal deform-
ities, and in nonunion bone fractures [1]. Drugs that
promote bone formation are thus in demand [2]. Alterna-
tively, adult stem or progenitor cells, such as mesenchy-
mal stem cells (MSCs), represent a promising resource for
new bone formation via cell-based tissue engineering.
These cells can be isolated from various adult tissues and
have the potential to differentiate and self-renew, as well
as to promote tissue repair through trophic effects on
other cell types and immune-regulatory activities [3–5]. In
particular, MSCs have the potential to differentiate into
multiple mesenchymal lineage cells, including adipocytes,
chondrocytes, and osteoblasts, underscoring the potential
of MSCs for musculoskeletal regenerative medicine [6].
To utilize MSCs effectively in regenerative medicine, a
clear understanding of how they respond to environ-
mental cues is essential. Early in their genesis, MSC re-
sponses to soluble and physical environmental stimuli
are likely determined, at least in part, by the availability
and organization of signaling molecules at the cell sur-
face membrane. Key cell membrane substructures in-
volved in such signaling molecule organization are lipid
microdomains known as membrane rafts. Membrane rafts
are cholesterol and sphingolipid-rich liquid-ordered phases
in the cell membrane that allow compartmentalization and
clustering of cell surface signaling molecules [7, 8]. Such
clustering promotes amplification, cross-talk, specificity,
and inhibitory regulation of cell signaling. A plethora of
cell signaling events are regulated in caveolae, a membrane
raft subtype [9, 10]. Signal regulation in caveolae is largely
attributed to the activity of their distinctive caveolin scaf-
folding proteins, which are essential for caveolae forma-
tion, as well as cholesterol binding and cholesterol
trafficking [11–16].
There are three types of caveolin proteins, which form
a hairpin loop in the cell membrane with their N-
termini and C-termini remaining in the cell cytoplasm
[17, 18]. Caveolin-1 (Cav-1) is most highly expressed in
fat and lung tissue [19–23], but it is also expressed in
many other tissues and differentiated cell types [21, 22,
24–31]. Caveolin-2 is usually coexpressed with Cav-1
and appears unable to form caveolae alone [20, 21, 32].
Caveolin-3 is highly expressed in muscle cells [22, 25,
33]. The cytoplasmic portion of Cav-1 contains a caveo-
lin scaffolding domain (CSD) that can bind to cell signal-
ing molecules and affect cell signal transduction, mostly
in an inhibitory fashion by direct interaction or as a re-
sult of caveolae endocytosis (see reviews by [9, 34]).
We have previously shown Cav-1 expression in adult
human bone marrow-derived MSCs, and that its level
increases during and negatively regulates the osteogenic
differentiation of MSCs [35]. This finding is consistent
with the phenotype of Cav-1 null mice, which show an
increased postnatal bone volume and bone formation
rate [36]. Furthermore, bone marrow MSCs isolated
from these mice have a greater tendency to mineralize in
response to osteogenic supplements in vitro [36]. In
agreement with other researchers, we hypothesize that
Cav-1 expression may increase during MSC osteogenesis
as a negative feedback mechanism to stabilize the
phenotype of osteogenically differentiated MSCs. How-
ever, in our previous study of Cav-1 knockdown MSCs,
broad gene expression analysis did not reveal any cell
signaling pathway early response genes affected by Cav-1
knockdown after 24 hours of stimulation with osteo-
genic supplements [35]. We therefore could not discern
the signaling pathways affected by Cav-1 MSCs induced
to osteogenically differentiate.
Cav-1 probably dampens pro-osteogenic signaling by
sequestering signaling mediators in cell surface caveolae
and/or driving their internalization via caveolae endocytosis.
In accordance with this idea, caveolae endocytosis of active
adhesion receptors (β1 integrins) and co-localized bone mor-
phogenetic protein (BMP) receptors contributes to the re-
pression of osteogenesis in rat MSCs seeded on soft
two-dimensional substrates [37]. Meanwhile, phosphoinosi-
tide 3-kinase (PI3K)/Akt signaling is a pathway commonly
downstream of integrin signaling. Akt signaling is dependent
on the generation of phosphatidylinositol 3,4,5-trisphosphate
(PIP3) at the cell membrane by PI3K phosphorylation of
phosphatidylinositol 4,5-bisphosphate (PIP2). We hypothe-
sized that PI3K/Akt signaling may be pro-osteogenic and
post-translationally regulated by Cav-1 and caveolae in hu-
man MSCs, because: PIP2 accumulates at the edges of cave-
olae [38]; Cav-1 regulates caveolae, integrin signaling, and
osteogenesis; and PI3K/Akt signaling is vital for endochon-
dral ossification [39, 40]. Here, we show that PI3K/Akt sig-
naling is influenced by Cav-1/cholesterol homeostasis, and
plays an important role in human MSC osteogenesis.
Methods
Tissue collection and harvesting of MSCs
Human bone marrow-derived MSCs were isolated with
patient consent and Institutional Review Board approval
(University of Washington, Seattle, WA, USA) from the
femoral heads of patients undergoing total hip arthro-
plasty using a standard plastic adhesion protocol. Cells
flushed from the bone marrow were pelleted and resus-
pended in isolation medium (α-minimal essential medium
+ 1× antibiotic–antimycotic, + 10 % MSC qualified fetal
bovine serum (FBS) (all GIBCO/Thermo Fisher Scien-
tific, Waltham, MA, USA) + 1 ng/ml fibroblast growth fac-
tor 2 (FGF-2; R&D Systems, Minneapolis, MN, USA),
seeded into T150 flasks (Corning Inc., Corning, NY, USA),
and incubated for 3–4 days at 37 °C in 5 % CO2, then
washed twice with phosphate-buffered saline (PBS,
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pH 7.4) and incubated in fresh isolation medium. When
colonies reached 80 % confluence, cells were reseeded at
1 × 106 cells/T150 flask in isolation medium. Medium was
changed every 3–4 days until cells reached 80–90 % con-
fluency, at which time cells were either frozen or pas-
saged. MSC isolates were routinely characterized with
respect to multilineage differentiation capabilities as
described previously [41].
Cell culture and treatments
For experiments, MSCs were expanded in growth medium
(high-glucose Dulbecco’s modified Eagle’s medium
(DMEM) containing L-glutamine and sodium pyruvate +
1× penicillin–streptomycin + 10 % MSC qualified FBS (all
GIBCO/Thermo Fisher Scientific) at 37 °C in 5 % CO2.
Growth medium was changed every 3–4 days until cells
reached 70–80 % confluence, at which time cells were
seeded for experiments. For osteogenic differentiation,
MSCs were seeded at 20,000 cells/cm2 and incubated in
osteogenic medium (growth medium+ 5 mM β-
glycerophosphate, 50 μg/ml ascorbic acid, 10 nM dexa-
methasone, 10 nM 1,25-dihydroxyvitamin D3; all Sigma-
Aldrich, St. Louis, MO, USA) or growth medium as a con-
trol. Medium was changed every 3 days.
For small interfering RNA (siRNA) transfection, MSCs
were seeded at 20,000 cells/cm2, incubated overnight,
washed in serum-free and antibiotic-free high-glucose
DMEM, and transfected with either 50 nM Human CAV1
ON-TARGETplus SMARTpool siRNA, 100 nM Human
AKT1 ON-TARGETplus SMARTpool siRNA, or 50 or 100
nM nontargeting control siRNA ON-TARGETplus Non-
targeting siRNA #2 (all Dharmacon/GE Life Sciences, Lafa-
yette, CO, USA) using DharmaFECT1 Transfection Re-
agent (Dharmacon/GE Life Sciences). DharmaFECT1 and
each siRNA were prepared at 10× the final concentration
used for transfection in serum-free and antibiotic-free high
glucose DMEM and incubated for 5 minutes at room
temperature. Each siRNA was then mixed 1:1 with the
DharmaFECT1 and incubated for 20 minutes at room
temperature. Each siRNA/DharmaFECT mix was then di-
luted 1:5 in antibiotic-free growth medium and added to
washed MSCs at 0.13 ml/cm2. The final volume of Dhar-
maFECT used was 0.08 μl/cm2. Twenty-four hours later,
the medium was replaced with either fresh growth
medium or osteogenic medium.
Disruption to all cholesterol membrane rafts was
achieved by 1-hour preincubation with methyl-β-
cyclodextrin (MβCD) in dimethyl sulfoxide (DMSO), used
at a final concentration of 1–10 mM, before addition of
control or osteogenic medium. MβCD pretreatment was
performed each time the culture medium was changed dur-
ing an experiment. As prolonged incubation with MβCD is
cytotoxic to MSCs, MβCD was not left on cells beyond the
1-hour period, and cell viability was assessed in parallel
wells using a commercial Live/Dead Assay (Life Technolo-
gies, Carlsbad, CA, USA) according to the manufacturer’s
instructions. PI3K/Akt signaling was inhibited using
LY294002 (Cell Signaling Technology, Danvers, MA, USA)
at a final concentration of 0.5–25 μM, which remained in
the culture medium for the duration of experiments, and
was added fresh with each medium change. Cholesterol
oxidation was achieved by 1-hour pretreatment with 0.5
U/ml cholesterol oxidase (CHOD, from Rhodococcus sp.;
Sigma-Aldrich) before addition of osteogenic medium.
Sucrose gradient subcellular fractionation of membrane rafts
A previously published method was used for subcellular
fractionation [42]. MSCs (1,140,000 cells at seeding)
were homogenized in 2 ml ice-cold 500 mM sodium car-
bonate pH 11.0 plus 1:100 protease inhibitor cocktail,
phosphatase inhibitor cocktail 2, and phosphatase inhibi-
tor cocktail 3 (all Sigma-Aldrich), sonicated, mixed 1:1
with 90 % sucrose in MBS buffer (25 mM 2-(N-morpho-
lino)ethanesulfonic acid , pH 6.5, 0.15 M NaCl), and
placed at the bottom of a 14 × 89 mm ultracentrifuge
tube (Beckman Coulter, Brea, CA, USA). 4 ml of 35 %
sucrose in 1:1 MBS:500 mM sodium carbonate was care-
fully layered over the homogenate, followed by 4 ml of
5 % sucrose in 1:1 MBS:500 mM sodium carbonate, and
samples were centrifuged at 192,072 × g in a Beckman
XL-70 Ultracentrifuge (SW40Ti rotor) for 22 hours. The
contents of the centrifuge tubes were collected carefully
in sequential 1 ml fractions from top to bottom.
Sucrose gradient subcellular fractionation of noncaveolar
and caveolar membrane rafts
Detergent-free cell lysates were prepared as already de-
scribed, and were placed at the bottom of a 14 × 89 mm2
ultracentrifuge tube (Beckman Coulter). According to the
protocol described by Yao et al. [43], 3 ml of 35 % sucrose in
1:1 MBS:500 mM sodium carbonate were layered on the lys-
ate mixture, followed by 4 ml of 21 % sucrose in 1:1
MBS:500 mM sodium carbonate, and 1 ml of 5 % sucrose in
1:1 MBS:500 mM sodium carbonate. Samples were then
centrifuged at 192,072 × g in a Beckman XL-70 Ultracentri-
fuge (SW40Ti rotor) for 22 hours. The contents of the cen-
trifuge tubes were collected carefully in sequential 0.5 ml
fractions from top to bottom, to make a total of 24 fractions.
Immunoblotting
Cells lysates were prepared in RIPA buffer plus 1:100
protease inhibitor cocktail, phosphatase inhibitor cock-
tail 2, and phosphatase inhibitor cocktail 3 (all Sigma-
Aldrich), and the protein concentration was determined
by BCA assay (Thermo Scientific™ Pierce™ Protein Biol-
ogy, Rockford, IL, USA). Equal volumes of protein (1 or
5 μg) were electrophoresed by SDS-PAGE in a 12 %
polyacrylamide gel and transferred to polyvinylidene
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fluoride (PVDF) blots which were blocked in 5 % milk or
5 % bovine serum albumin (BSA; Sigma-Aldrich) in Tris-
buffered saline + 0.05 % Tween 20 (TBST), and then incu-
bated overnight at 4 °C with either rabbit anti-Akt or anti-
serine 473 phosphorylated Akt (p-Akt) (1:1000 in TBST +
5 % BSA; both Cell Signaling Technology), or rabbit anti-
Cav-1 (1:5000 in TBST + 2.5 % milk; BD Biosciences,
Franklin Lakes, NJ, USA), or rabbit anti-GM130 (1:1000
in TBST + 5 % BSA; Cell Signaling Technology). Second-
ary antibodies were Amersham ECL donkey anti-rabbit or
sheep anti-mouse horseradish peroxidase (HRP)-linked
IgG antibody (both GE Healthcare UK Limited, Little
Chalfont, UK). HRP activity was detected using Super-
signal West Dura, Extended Duration Substrate (Thermo
Scientific™ Pierce™ Protein Biology) and the chemilumin-
escence reaction was visualized using a FOTO/Analyst® Fx
CCD imaging system (Fotodyne Inc., Hartland, WI, USA).
Densitometric analysis of immunoblots
The intensity of bands on western blots was measured
using grayscale images in Image J software (http://imagej.
nih.gov/ij/). A tall, narrow, rectangle of constant shape
was used to identify lanes in each western using the “Rect-
angular Selections” tool. The intensity of bands in each
lane was then measured using the Analyze >Gels > Plot
Lanes function. Peaks corresponding to bands of interest
where defined from background noise using the “Straight
Line” selection tool. The “Wand” tool was then used to se-
lect peaks to measure, and the Analyze >Gels > Label Peaks
function used to determine peak size, which represents the
intensity of the corresponding band. Band intensity values
were exported to Excel 2010 (Microsoft Corporation, Red-
mond, WA, USA) and intensities of phosphorylated bands
(e.g., p-Akt bands) normalized to the intensity of total pro-
tein signal (e.g., Pan Akt) from the same sample.
Alkaline phosphatase assay
Cultures in 24-well plates were washed in PBS, lysed
in 150 μl of 0.5 % Triton X-100 in water for 10 mi-
nutes at room temperature, and frozen and thawed
twice. Then 100 μl lysate was assayed spectrophoto-
metrically using an equal volume of substrate buffer
(4 mg/ml 4-nitrophenyl phosphate (pNPP; Sigma-
Aldrich)), mixed 1:1 with AMP buffer (4.8 % 2-
amino-2-methyl-1-propanol (2-AMP; Sigma-Aldrich)),
2 mM MgCl2, pH 10.15). A415 values were used to
calculate alkaline phosphatase (ALP) activity and
expressed as a function of DNA.
Picogreen assay for DNA
DNA was quantified using Quant-iT™ PicoGreen® dsDNA
reagent (Invitrogen/Thermo Fisher Scientific, Carlsbad,
CA), a fluorescent dsDNA stain (excitation 480 nm, emis-
sion 520 nm), according to the manufacturer’s instructions.
A lambda phage DNA standard was used to quantify DNA
from the fluorescence readings.
Alizarin red staining
Cultures were washed in PBS, fixed in 60 % isopropanol
(diluted in tap water), washed in tap water, and stained
with 2 % Alizarin red S solution, pH 4.2, for calcium deposits
(Rowley Biochemical Institute, Danvers, MA, USA). Cultures
were washed thoroughly with tap water before scanning
and imaging. Retained stain was solubilized using 0.5 ml of
10 % cetylpyridinium chloride in 10 mM Na2HPO4,
Fig. 1 PI3K/Akt signaling is required for MSC osteogenesis. MSCs
were cultured in control growth medium (GM) or osteogenic
medium (OM) to induce osteogenesis. a Effect of LY294002. MSCs in
OM were incubated in the presence or absence of different
concentrations of the PI3K inhibitor LY294002, or DMSO vehicle
alone. Osteogenesis was assessed by Alizarin red staining for matrix
mineralization on day 21 (top panel, triplicate cultures shown), and
measuring alkaline phosphatase (ALP) activity on day 4 (bottom
panel). Values represent mean ± standard error of the mean (SEM) (n
= 4). LY294002 inhibited osteogenesis in a dose-dependent manner,
suggesting that PI3K/Akt signaling is required for human MSC
osteogenesis. b Effect of siRNA-mediated Akt knockdown. MSCs
were transfected with scramble control siRNA (Ctrl) or Akt siRNA
before incubation in GM or OM for 4 days and measurement of ALP
activity. Akt siRNA treatment significantly reduced ALP activity
induced by OM. Values represent mean ± S.E.M (n =4).
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pH 7.0, at room temperature for 15 minutes and quantified
spectrophotometrically at 570 nm and normalized to the
DNA content measured in cell lysates of duplicate wells of
each sample.
Statistical analysis
All statistical analysis was performed using Student’s
two-tailed t test on two groups containing at least three
samples each, with statistical significance at p ≤0.05.
Results
To test our hypothesis that PI3K/Akt signaling is pro-
osteogenic and regulated by Cav-1 and caveolae in hu-
man MSCs, we confirmed that PI3K/Akt signaling is re-
quired for human MSC osteogenesis, by first examining
the effect of treatment with the pharmacological
inhibitor of PI3K, LY294002. LY294002 dramatically
inhibited MSC osteogenesis in a dose-dependent man-
ner, as measured by ALP activity, an early marker of
osteogenic differentiation, and matrix mineralization
based on Alizarin red staining, which indicates terminal
osteogenic differentiation (Fig. 1a). Furthermore, treat-
ment of MSCs with Akt-specific siRNA significantly re-
duced induction of osteogenesis (Fig. 1b). These data
indicate that PI3K/Akt signaling is required for osteo-
genic differentiation of human bone marrow-derived
MSCs in vitro.
To begin to determine the role of membrane rafts in pro-
osteogenic PI3K/Akt signaling, we probed the localization
of Akt to membrane rafts during MSC osteogenesis. MSCs
were cultured in control growth medium or growth
medium containing osteogenesis-inducing supplements.
After 10 days of culture in the presence of osteogenic
supplements, MSCs express Col1a2 and higher levels of
Cav-1 [35]. Lysates from MSC cultures were therefore
harvested after 10 days. They were then fractionated
using a previously published sucrose gradient flotation
method [42]. By this fractionation method, Cav-1 protein
is detected around the fifth to sixth fractions containing
buoyant lipid rafts (Fig. 2) [35, 42]. Total Akt expression
was probed in all gradient fractions from MSCs cultured
with or without osteogenic supplements. Strikingly, a por-
tion of Akt appeared colocalized with Cav-1 in buoyant
membrane fractions in MSCs cultured with osteogenic
supplements (Fig. 2). In MSCs cultured without osteo-
genic supplements, Akt mostly remained within intracel-
lular fractions as indicated by the presence of the Golgi
marker GM130 (Fig. 2). To investigate whether Akt accu-
mulation in buoyant rafts was in caveolar membrane rafts
specifically and whether this Akt was active, we used a
modified sucrose gradient subcellular fractionation
method that allows the separation of caveolar and nonca-
veolar rafts, and probed fractions for Ser-473 p-Akt [43].
This revealed that any buoyant fraction p-Akt in control
MSCs was confined to noncaveolar membrane rafts
(Fig. 3). However, incubation of MSCs in osteogenic
medium caused detectable translocation of p-Akt into
caveolar membrane rafts (Fig. 3).
Cav-1 is known to positively interact with PI3K/Akt
signaling in other, differentiated, cell types [9]. However,
Fig. 2 Akt is present at high levels in membrane rafts in osteogenically differentiating MSCs. A sucrose density flotation method was used to
determine Akt localization to membrane rafts in MSCs cultured in either growth medium (GM) or osteogenic medium (OM). In this method,
buoyant membrane rafts float to the upper fractions (4–7) of the 12-fraction sucrose gradient upon ultracentrifugation, separating from intracellular
fractions that remain at the bottom of the gradient. Top panel: immunoblotting of the fractions for the Golgi marker GM130 indicates intracellular
fractions (9–12). Middle panel: immunoblotting with a pan-Akt antibody shows that Akt was mostly located within intracellular fractions. However,
significantly higher levels of Akt were detected in membrane rafts from cells cultured in OM on day 10. This is shown by overlapping distribution with
caveolin-1 (Cav-1) in buoyant membrane rafts. Bottom panel: immunoblotting for Cav-1 indicates the presence of membrane rafts floating in the upper
fractions. This result is representative of four different human bone marrow MSC donor sources tested. Molecular weight standards are shown to the
left of the immunoblots
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as Cav-1 inhibits MSC osteogenesis [35] and PI3K/Akt
signaling is pro-osteogenic (Fig. 1), we postulated that
the movement of p-Akt to caveolar membrane rafts
during osteogenesis progression could be a negative
regulatory event. To test this, we isolated protein from
control siRNA and Cav-1 siRNA-transfected MSCs at
multiple time points following stimulation with osteo-
genic supplements, and probed for Akt phosphoryl-
ation/activation by western blotting. We found that Akt
was phosphorylated in MSCs stimulated with osteo-
genic supplements, and this activation was modestly
enhanced in Cav-1 knockdown MSCs (Fig. 4). Con-
versely, when cells were treated with the cholesterol
chelator MβCD, which strips cholesterol from both
caveolar and noncaveolar membrane rafts, Akt phos-
phorylation was inhibited (Fig. 5). These results suggest
that localization of Akt in noncaveolar lipid rafts is im-
portant for osteogenesis. Accordingly, MβCD dose-
dependently inhibited ALP activity induced after 4 days
of incubation of MSCs with osteogenic supplements
(Fig. 5). We confirmed that these affects were not due
to cytotoxicity by performing Live/Dead staining in
parallel cultures (Fig. 5e). Cholesterol-rich membrane
rafts are therefore required for Akt phosphorylation
Fig. 3 Phosphorylated Akt (p-Akt) is relocated to caveolae in
osteogenically differentiating MSCs. a A modified sucrose gradient
flotation method [43] was used to separate membrane rafts with
different buoyancies to distinguish noncaveolar membrane rafts
from caveolae. b Cav-1 protein was detected by immunoblotting in
the middle fractions of the gradient, indicating the presence of
caveolae. c, d p-Akt was much more abundant in the noncaveolar
membrane raft fractions. c No p-Akt was detected in the caveolar
fraction of MSCs cultured in standard growth medium (GM). d However,
p-Akt was detected in the caveolar fraction of MSCs cultured in the
presence of osteogenic supplements for 10 days (OM). These
results suggest that a portion of p-Akt relocated to caveolae during
osteogenesis. Molecular weight standards are indicated on the
right of the immunoblot panels. Data shown are representative of
three replicates
Fig. 4 Osteogenic supplement-induced Akt phosphorylation is modestly
enhanced in Cav-1 knockdown MSCs. MSCs transfected with control
(Ctrl) or Cav-1 (Cav) small interfering RNA (siRNA) were serum starved
overnight, and then stimulated with osteogenic supplements (OM).
Immunoblot analysis of cellular proteins harvested at the indicated
time points after stimulation with OM showed that Akt is phosphorylated
after 5 minutes incubation in OM (top panel). There is a moderate
increase in Akt phosphorylation in MSCs transfected with Cav-1 siRNA
and incubated in OM for 5 minutes and 40 minutes compared with
MSCs transfected with control nontargeting siRNA. This result is
representative of three replicates with different MSC sources. The
densitometric data for all replicates are presented in the bar graph
(bottom panel), which shows the mean p-Akt/Akt signal for each
sample relative to control samples in the same experiment at t = 0.
Densitometric quantification of bands was achieved using NIH Image J
software. Values represent mean ± SEM (n =4). The increase in p-Akt
signal in MSCs transfected with Cav-1 siRNA and incubated in OM was
statistically significant at 40 minutes
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and MSC osteogenesis, while movement of p-Akt to ca-
veolae lipid rafts could be inhibitory for pro-osteogenic
Akt signaling.
To further test how caveolar lipid rafts affect Akt ac-
tivity, we attempted to displace Cav-1 from caveolae by
means of cholesterol oxidation. Treatment of cells with
CHOD has been reported to cause the reversible reloca-
tion of Cav-1 from cell surface caveolae to the Golgi ap-
paratus in fibroblasts [44]. We confirmed that treatment
with CHOD caused Cav-1 to move out of caveolae in
MSCs (Fig. 6a). When this pretreatment was adminis-
tered for the duration of osteogenic supplement-induced
osteogenesis, matrix mineralization was enhanced
(Fig. 6b). Furthermore, when MSCs were pretreated with
CHOD, Akt phosphorylation in response to osteogenic
supplements was enhanced (Fig. 6c, d). Taken together,
our results suggest that Akt activation is important for
osteogenic supplement-induced MSC osteogenesis, and
that noncaveolar lipid rafts are required for this signal-
ing, while Akt localization to Cav-1-containing caveolae
lipid rafts may suppress Akt activation and osteogenic
signaling.
Discussion
Previously, we reported that siRNA-mediated knock-
down of Cav-1 expression in human MSCs enhances
MSC osteogenesis [35]. Here, we show that Akt is
phosphorylated in MSCs stimulated with osteogenic
supplements and that this is enhanced in Cav-1 siRNA-
transfected MSCs. We also show that PI3K/Akt signaling
is essential for human MSC osteogenesis in a manner
dependent on cholesterol-rich membrane rafts, and that
p-Akt translocates to caveolar membrane rafts during
osteogenesis. Furthermore, CHOD treatment displaces
Cav-1 from caveolae, enhancing p-Akt signaling and MSC
osteogenesis. Therefore, p-Akt localization to caveolae
Fig. 5 Depletion of MSC membrane cholesterol reduces Akt phosphorylation and osteogenic supplement-induced alkaline phosphatase (ALP)
activity. MSCs were treated with standard growth medium (GM), treated with growth medium with osteogenic supplements (OM), or pretreated
for 1 hour with methyl-β-cyclodextrin (MβCD) before addition of OM supplements. a, b Immunoblotting (western blot, WB) showed that 10 mM
MβCD suppressed phosphorylation of Akt in OM (a), with no change in total Akt levels (b). Molecular weight standards are shown on the left of
the immunoblot. These results are representative of three replicates with different MSC sources. c Densitometric analysis of the phosphorylated
Akt (p-Akt) signal normalized to total Akt is shown for all three replicates. Values represent mean ± SEM (n =3). d Effect of MβCD treatment on
OM-induced ALP activity. Significant suppression of ALP activity was seen at 10 mM MβCD. Values represent mean ± SEM (n = 4). e Three
representative images from Live/Dead staining of cells exposed to 10 mM MβCD in replicate wells of samples in (d). Bar = 100 μm. Results shown
here are representative of at least three different MSC populations studied, and suggest the requirement of membrane cholesterol for PI3K/Akt signal-
ing and induction of osteogenesis in human MSCs
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may act as an inhibitory negative feedback mechanism to
suppress continued MSC osteogenesis. Taken together,
our results suggest a pathway in which PI3K/Akt signaling
is required for human MSC osteogenic differentiation,
during the progression of which Cav-1 expression in-
creases [35], and p-Akt relocates to Cav-1-containing
caveolar membrane rafts, thus contributing to the sup-
pression of continued osteogenesis (Fig. 7).
In mice, there is substantial evidence that PI3K/Akt
signaling is important for osteogenesis and endochon-
dral ossification (reviewed in [45]). Knockout of Akt
negatively affects murine endochondral ossification [39,
40]. Similarly, longitudinal bone growth in mouse em-
bryonic tibiae is suppressed by inhibition of PI3K/Akt
signaling using the same inhibitor as used here,
LY294002 [46]. Akt activity is also required for the
growth of isolated mouse metatarsal bones in vitro both
during the chondrogenic phase of the process and for
osteoblast maturation [47].
There is also substantial evidence that PI3K/Akt sig-
naling is required for murine osteogenesis from in vitro
cell culture studies. In cultures of 2T3 osteoblast precur-
sor cells isolated from mouse calvaria, BMP-induced
osteogenesis requires PI3K/Akt signaling [48]. This is
also true for osteogenesis of mouse embryonic fibro-
blasts (MEFs), murine bone marrow-derived MSCs, and
in the mouse MSC line C3H10T1/2 [47, 49]. Studies in
murine cells also suggest that PI3K/Akt is required early
in the transcriptional activation of osteogenesis. For ex-
ample, in an immature osteoblastic cell line derived from
Fig. 6 Cholesterol oxidase (CHOD) treatment enhances MSC osteogenesis. a MSCs were treated for 1 hour with or without CHOD, and then
caveolae were isolated by sucrose gradient flotation. Fractions expected to contain caveolae (see Fig. 3) were immunoblotted for caveolin-1 (Cav-
1). Results show that CHOD pretreatment displaces Cav-1 from buoyant caveolae membrane rafts. b, c MSCs were treated with standard growth
medium (GM), treated with growth medium with osteogenic supplements (OM), or pretreated for 1 hour with CHOD before addition of growth
medium with osteogenic supplements (CHOD). b After continuous treatment for 10 days with medium change every 3 days, Alizarin red staining
revealed that OM-induced matrix mineralization was accelerated in CHOD-treated MSCs (quadruplicate cultures shown). c Immunoblotting
showed that 5 minutes after initial CHOD treatment, phosphorylated Akt (p-Akt) levels increased, while total Akt (Pan Akt) remained unchanged.
These results are representative of three replicates with different MSC sources. d Densitometric analysis is shown for all three replicates. Values
represent mean ± SEM (n =3). This confirmed a significant increase in p-Akt/Akt levels upon CHOD treatment, suggesting that pretreatment with
CHOD enhances OM-mediated induction of PI3K/Akt signaling in MSCs. Ctrl control
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mouse calvaria (MC3T3-E1), Runx2 overexpression
upregulates expression of the PI3K subunits p85 and
p110β, as well as Akt protein in these cells, and recipro-
cally PI3K/Akt signaling is required for the DNA bind-
ing and transcriptional activities of Runx2 [50]. It
therefore appears that Runx2 and PI3K/Akt signaling act
in a positive feedback loop to induce osteogenesis, and
PI3K/Akt signaling is essential for the induction of
Runx2 expression and activity. The exact mechanism for
this is unknown, however, because Akt does not appear
to directly phosphorylate Runx2. Nevertheless, PI3K/Akt
signaling is required for Runx2-induced osteogenesis of
C3H10T1/2 cells [48], and BMP-2-induced expression of
Runx2 in C3H10T1/2 cells and mouse bone marrow
stromal cells [47, 49]. Furthermore, in 2T3 cells, Akt
may be required for translocation of BMP signaling in-
termediates, the Smads, to the cell nucleus [48]. Here,
we have shown that PI3K/Akt signaling is required for
the osteogenic differentiation of human bone marrow-
derived MSCs in vitro. Furthermore, we show that this
signaling is influenced by cholesterol-rich membrane
rafts.
Knockdown of Cav-1 expression and CHOD treatment
in human MSCs enhanced Akt activation in response to
osteogenic supplements. CHOD produces oxysterols by
cholesterol oxidation. In turn, oxysterols are known to
suppress Cav-1 expression and cause Cav-1 translocation
out of caveolae [44, 51] and to promote MSC osteogen-
esis [52]. Our findings reported here therefore agree
with a pathway in which PI3K/Akt signaling positively
contributes to MSC osteogenesis, while Cav-1 expres-
sion increases during osteogenesis and, via caveolae,
dampens this pathway as one means to suppress contin-
ued osteogenesis (Fig. 7).
Meanwhile, our results also suggest that some mem-
brane cholesterol is required for Akt activation and
osteogenesis. This is probably required for Akt activation
in noncaveolar membrane rafts (Fig. 3). In agreement
with a requirement for cholesterol in osteogenesis,
others have found that some cholesterol biosynthesis in-
hibitors (statins) can inhibit the osteogenesis of mouse
marrow stromal cells (M2-10B4 cells), and this can be
rescued by supplementation with the cholesterol biosyn-
thesis intermediate, mevalonic acid, which is produced
downstream of statin inhibition [53].
It must be noted that statins have also been shown to
enhance MSC osteogenesis in vitro [54, 55]. There is
also evidence indicating that systemic statin treatment
enhances tissue repair, particularly in bone [56]. This
may still agree with our hypothetical pathway in Fig. 7,
due to the dual role of cholesterol in both noncaveolae
and caveolae rafts. Intracellular cholesterol levels and
Cav-1/caveloae activity are directly, functionally linked;
an increase in intracellular cholesterol levels promotes
Cav-1-directed cholesterol efflux and caveolae forma-
tion, and internalization of free cholesterol promotes
Cav-1 expression [51, 57]. Therefore, if intracellular
cholesterol levels are below a certain threshold through
statin treatment, cell surface caveolae levels may be low,
thus preventing Cav-1/caveolae suppression of contin-
ued osteogenesis. However, in mouse osteoblasts it has
been shown that statins can directly activate osteogenic
PI3K/Akt signaling via membrane-associated Ras [58].
The pro-osteogenic effects of statins may therefore not
be completely attributed to their cholesterol biosynthetic
inhibitory activities.
Conclusions
Similar to the scenario in mice, PI3K/Akt is an essential
pathway for human MSC osteogenesis. Noncaveolar
cholesterol-rich lipid rafts appear to be important for acti-
vation of PI3K/Akt signaling and osteogenesis. However,
Cav-1, the scaffolding protein of caveolae membrane rafts
that suppresses osteogenesis in both murine and human
MSCs, may suppress PI3K/Akt signaling within caveolae.
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